AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
206 hedge funds and large institutions have $1.43B invested in AMAG Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 72 increasing their positions, 57 reducing their positions, and 21 closing their positions.
143% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 21
42% more capital invested
Capital invested by funds: $1.01B → $1.43B (+$420M)
26% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 57
16% more funds holding
Funds holding: 178 → 206 (+28)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
97% less call options, than puts
Call options by funds: $7.83M | Put options by funds: $260M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$30.7M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$26.2M |
| 3 |
Renaissance Technologies
New York
|
+$15.3M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$14.9M |
| 5 |
JP Morgan Chase
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$57.5M |
| 2 |
SIM
Stelliam Investment Management
New York
|
-$16.6M |
| 3 |
NRC
North Run Capital
Boston,
Massachusetts
|
-$13.7M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$12M |
| 5 |
State Street
Boston,
Massachusetts
|
-$11.3M |
AMAG Hedge Fund Activity: Q4 2016 in Review
206 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2016, worth a combined $1.43B — up 42% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new AMAG positions and 21 closed out — a net gain of 30 holders — while 72 added to existing stakes and 57 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $30.7M. The largest seller was Adage Capital Partners, cutting an estimated $57.5M.
- 206 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2016, up from 178 in Q3 2016.
- Funds reported $1.43B of AMAG Pharmaceuticals stock for Q4 2016, up 42% quarter-over-quarter.
- 51 funds opened new AMAG Pharmaceuticals positions in Q4 2016 and 21 closed out, a net change of +30 holders.
- The largest AMAG Pharmaceuticals buyer in Q4 2016 was Consonance Capital Management, an estimated $30.7M added.
- The largest AMAG Pharmaceuticals seller in Q4 2016 was Adage Capital Partners, an estimated $57.5M sold.
Based on aggregated 13F filings for Q4 2016.